Oppenheimer & Co. Inc. Increases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Oppenheimer & Co. Inc. lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 6.5% in the third quarter, HoldingsChannel.com reports. The fund owned 44,893 shares of the company’s stock after acquiring an additional 2,748 shares during the period. Oppenheimer & Co. Inc.’s holdings in TransMedics Group were worth $7,048,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of TMDX. International Assets Investment Management LLC purchased a new position in TransMedics Group in the second quarter worth $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group during the 3rd quarter worth $55,000. J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC grew its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Farther Finance Advisors LLC grew its position in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

TransMedics Group stock opened at $92.73 on Thursday. The firm has a fifty day simple moving average of $129.09 and a two-hundred day simple moving average of $139.89. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $61.98 and a twelve month high of $177.37. The company has a market capitalization of $3.11 billion, a PE ratio of 98.65 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The company’s revenue was up 63.7% on a year-over-year basis. Research analysts expect that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Robert W. Baird lowered their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Stephens boosted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Oppenheimer lowered their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.